(Source: Ergomed plc) London, UK - 6 Febuary 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces positive top-line results from a Phase II clinical trial of Lorediplon in patients with insomnia with its co-development partner Ferrer. Highlights: Both 5 and 10mg Lorediplon met the primary endpoint with high statistical significance, indicating the drug has strong efficacy in sleep maintainance throughout the night when compared to placebo Lorediplon was well tolerated with an acceptable safety profile including on assessment of next day residual...
↧